Nebkliq (Amlodipine Besilate, Nebivolol Hydrochloride)

Amlodipine besilate and nebivolol hydrochloride, the active ingredients in Nebkliq, are a calcium‑channel blocker and a beta‑1 selective blocker respectively, presented as an oral tablet for systemic use. The combination is indicated for the treatment of hypertension in adult patients. GNH USA supplies Nebkliq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebkliq is used to manage high blood pressure by targeting vascular tone and cardiac output. - Essential hypertension: reduces systolic and diastolic pressure in patients with primary hypertension. - Isolated systolic hypertension: helps control elevated systolic readings, especially in older adults. - Hypertension requiring combination therapy: provides dual action when monotherapy is insufficient.

Common side effects are generally mild and related to the vasodilatory and beta‑blocking actions.

Common Side Effects: - Headache: mild to moderate headache, often transient. - Peripheral edema: swelling of ankles or feet due to fluid accumulation. - Flushing: sensation of warmth and redness, especially after the first dose. - Dizziness: light‑headedness, particularly when standing quickly. - Fatigue: general tiredness or reduced energy levels. - Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Angioedema: swelling of face, lips, tongue, or throat requiring urgent care. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Bronchospasm: tightening of airway muscles, especially in patients with asthma. - Myocardial infarction: rare occurrence of heart attack. - Heart block: abnormal heart rhythm that may need medical intervention.

Before initiating Nebkliq, clinicians should evaluate patient history and monitor for potential risks. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Cardiac function assessment: evaluate heart rate and rhythm, especially in patients with conduction disorders. - Concomitant medication review: consider interactions with other antihypertensives or CYP2D6 substrates. - Hepatic impairment caution: dose adjustment may be needed in moderate to severe liver disease. - Discontinuation guidance: avoid abrupt cessation to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebkliq may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase nebivolol plasma levels. - Other potent antihypertensives (e.g., clonidine, hydralazine): risk of additive blood pressure lowering. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): can enhance bradycardia.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive effect, monitor electrolytes. - NSAIDs: can reduce antihypertensive efficacy, watch renal function. - Antidiabetic agents: blood glucose may be affected, adjust monitoring. - Lipid‑lowering drugs (e.g., statins): monitor for increased statin concentrations. - Alcohol: may enhance dizziness and hypotension.